End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
14.84 CNY | +3.56% | +3.85% | -36.88% |
04-26 | Walvax Biotechnology's Profit Drops 92%, Operating Income Slids 28% in Q1 2024 | MT |
04-25 | Walvax Biotechnology's Unit to End COVID-19 Vaccine Trial | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-36.88% | 3.28B | |
-3.45% | 87.17B | |
+1.97% | 40.1B | |
+56.59% | 25.12B | |
-14.82% | 15.59B | |
-8.82% | 12B | |
-16.29% | 11.8B | |
-41.58% | 11.8B | |
+6.14% | 8.81B | |
-10.64% | 8.24B |
- Stock Market
- Equities
- 300142 Stock
- News Walvax Biotechnology Co., Ltd.
- Walvax’s COVID-19 Vaccine Candidate Stronger Against Omicron Versus Sinovac’s Jab